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Abstract
Background: Hematopoietic stem cell (HSC) transplantation has been widely applied to the treatment of malignant
blood diseases. However, limited number of functional HSCs hinders successful transplantation. The purpose of our
current study is to develop a new and cost-efficient medium formulation that could greatly enhance the expansion
of HSCs while retaining their long-term repopulation and hematopoietic properties for effective clinical transplantation.
Methods: Enriched human CD34+ cells and mobilized nonhuman primate peripheral blood CD34+ cells were
expanded with a new, cost-efficient expansion medium formulation, named hematopoietic expansion medium
(HEM), consisting of various cytokines and nutritional supplements. The long-term repopulation potential and
hematologic-lineage differentiation ability of expanded human cells were studied in the non-obese diabetic/
severe combined immunodeficiency mouse model. Furthermore, the efficacy and safety studies were performed
by autologous transplantation of expanded primate cells in the nonhuman primate model.
Results: HEM could effectively expand human CD34+ cells by up to 129 fold within 9 days. Expanded HSCs retained long-
term repopulation potential and hematologic-lineage differentiation ability, as indicated by (1) maintenance (over unexpanded
HSCs) of immunophenotypes of CD38−CD90+CD45RA−CD49f+ in CD34+ cells after expansion; (2) significant presence of
multiple human hematopoietic lineages in mouse peripheral blood and bone marrow following primary transplantation; (3)
enrichment (over unexpanded HSCs) in SCID-repopulating cell frequency measured by limiting dilution analysis; and (4)
preservation of both myeloid and lymphoid potential among human leukocytes from mouse bone marrow in week 24 after
primary transplantation or secondary transplantation. Moreover, the results of autologous transplantation in nonhuman
primates demonstrated that HEM-expanded CD34+ cells could enhance hematological recovery after myelo-suppression. All
primates transplanted with the expanded autologous CD34+ cells survived for over 18months without any noticeable
abnormalities.
Conclusions: Together, these findings demonstrate promising potential for the utility of HEM to improve expansion of HSCs
for clinical application.
Keywords: Long-term HSC, Ex vivo expansion, Human cord blood, Transplantation, NOD/SCID mice, Nonhuman primates
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: xding@pharmacy.arizona.edu; yjiang@biopharmagen.com
†Yu Zhang, Bin Shen and Xin Guan contributed equally to this work.
1Biopharmaceutical R&D Center, Chinese Academy of Medical Sciences &
Peking Union Medical College, Suzhou 215126, China
Full list of author information is available at the end of the article
Zhang et al. Stem Cell Research & Therapy          (2019) 10:173 
https://doi.org/10.1186/s13287-019-1275-0
Background
Hematopoietic stem cells (HSCs) are capable of self-
renewal and differentiation into all types of blood cells,
including those of the erythroid, myeloid, and lymphoid
lineages. HSCs are used as cellular therapeutic agents in
the clinic for treating a variety of hematopoietic malig-
nancies, including leukemia [1–4].
At present, three different sources of HSCs are used for
transplantation, including umbilical cord blood (UCB),
mobilized peripheral blood (mPB), and bone marrow
(BM) [5, 6]. Due to limited availability of these cells for
clinical transplantation, many attempts at ex vivo expan-
sion have been made in the past to obtain a sufficient
number of transplantable HSCs [7–9]. A vast majority of
strategies for expanding HSCs ex vivo are focused on
regulating the renewal and survival of HSCs mediated by
intrinsic factors (e.g., transcription factors and signaling
molecules) or environmental cues (e.g., cytokines, chemo-
kines, stromal cells, and adhesion molecules) [10, 11].
Reasonable stem cell expansion has been achieved by co-
culturing with BM mesenchymal stromal cells, with im-
mortalized stromal cells [12–14] or by over-expression of
self-renewal genes such as HOXB4 [15–17] and Sall4b [18,
19]. However, these approaches involve the manipulation
of the stromal environment or perturbation of the HSC
genome, at the risk of unintended adverse effects, such as
carcinogenesis. Therefore, it is imperative to develop a
simple but effective approach for HSC expansion. Over
the past two decades, various cytokines, small molecules,
and chemicals have been used to expand HSCs ex vivo, in-
cluding thrombopoietin (TPO) [20], Fms-related tyrosine
kinase 3 ligand (Flt-3 L) [21], granulocyte colony-
stimulating factor (G-CSF) [22], interleukin (IL)-3, -6, -11
[23, 24], stem cell factor (SCF) [25–27], angiopoietin
(Ang)-1 [28], StemRegenin 1 (SR1) [29], and tetraethylen-
pentamin (TEPA) [30]. However, only limited success has
been achieved with stem cell expansion by using a mixture
of growth factors/cytokines/chemicals. In addition, the
high cost of culturing HSCs ex vivo is another barrier for
industrialization and clinical use. Thus, there is still a large
need to further optimize efficiency and decrease cost.
In addition, most in vivo studies in the past have been
related to engraftment in murine models, which is lim-
ited by their relatively short life span and the species dif-
ferences between humans and mice. Conversely, the
overwhelming homology between humans and primates
allows for many of the same cytokines, growth factors,
drugs, and therapeutic regimens to be used, and the
regulation of hematopoiesis in primates is also physiolo-
gically similar to humans [31, 32]. Thus, nonhuman pri-
mates are considered to be a valuable mammalian model
for cell transplantation studies.
In the present study, we developed a new and cost-
efficient CD34+ HSC expansion medium formulation
(denoted as HEM), which could effectively expand HSCs
while retaining their long-term repopulation and
hematopoietic ability on a large scale within 9 days. We
also verified the long-term engraftment and repopulating
ability of the expanded cells in the non-obese diabetic/
severe combined immunodeficiency (NOD/SCID) mouse
model and assessed their safety and efficacy in the non-
human primate model.
Methods
Animals
All experiments that involved the use of animals were
strictly conducted according to the standard guidelines.
Female NOD/SCID mice (specific pathogen-free; 6
weeks old, weight 16.0–17.6 g), obtained from the Ex-
perimental Animal Center of Soochow University
(Suzhou, China), were used for human UCB HSCs trans-
plantation. The experimental protocols used for mice
were approved by the Institutional Animal Care and Use
Committees of Soochow University (IACUC permit
number: SYXK (Su) 2013-0064).
Cynomolgus primates were obtained from the Medical
Primate Research Center of the Institute of Medical
Biology, Chinese Academy of Medical Sciences, and
were housed and bred according to the Guidelines of the
Experimental Animals Ethics Committee at the Institute
of Medical Biology of the Chinese Academy of Medical
Sciences (Permit Number YISHENGLUNZI [2014] 07),
which complied with the humane regulations of replace-
ment, refinement, and reduction (the 3 Rs).
Isolation of CD34+ cells
Fresh UCB samples (within 6–8 h of collection) and cryo-
preserved specimens from anonymous donors were pro-
vided by the Nanjing Medical University Affiliated Suzhou
Municipal Hospital (Suzhou, China). The study was ap-
proved by the Hospital’s Ethics Committee and Research
Ethics Advisory Committee. CD34+ cells were enriched
from mononuclear cells (MNCs) using the magnetic-
activated cell sorting (MACS) immunomagnetic absorp-
tion column separation device and the CD34 MicroBead
kit according to the manufacturer’s instructions (Miltenyi
Biotec, Bergisch Gladbach, Germany). MNCs were ob-
tained by density gradient centrifugation using Ficolle-
Hypaque Premium (GE healthcare, NJ, USA). The purity
of isolated CD34+ cells ranged from 90 to 99% as deter-
mined by flow cytometry using an anti-human CD34
mAb conjugated with phycoerythrin (PE; BD Biosciences,
NJ, USA).
CD34+ stem cells from cynomolgus primates (n = 11)
were mobilized with recombinant human (rh) G-CSF
(200 μg/kg) and rhSCF (200 μg/kg) administered s.c. for
five successive days. PB samples (15–20mL each) were
then collected at 24 and 48 h after the final injection.
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CD34+ cell enrichment was achieved using anti-CD34
IgM and MACS IgM microbeads (Miltenyi Biotec, Ber-
gisch Gladbach, Germany) according to the manufac-
turer’s instructions and as described previously [33, 34].
The average purity of CD34+ cells in the enriched prod-
uct was about 69.6% (ranging from 61.5 to 76%) as de-
termined by flow cytometry. CD34+ and CD34− cells
were also cryopreserved separately and were revived at
the time of autologous transplantation.
Condition optimization for human HSC expansion
CD34+ cells derived from human UCB were cultured in
Iscove’s modified Dulbecco’s medium (IMDM) with
added nutrition supplements [25, 27, 35, 36], which con-
sisted of putrescine (100 μM), selenium (5 ng/mL), insu-
lin (25 μg/mL), transferrin (50 μg/mL), human serum
albumin (1%), and B-27 Supplement (Life Technologies,
NY, USA). Then, different combinations and concentra-
tions of growth factors were added to figure out the op-
timal conditions, which could best support human
CD34+ cell expansion ex vivo (Table 1). Agents tested
included SCF (200 ng/mL), Flt-3 L (200 ng/mL), TPO
(range 0–100 ng/mL), interleukin-3 (IL-3, range 0–100
ng/mL), G-CSF (range 0–100 ng/mL), GM-CSF (range
0–100 ng/mL), and SR1 (0.5–1 μM; Selleck Chemicals,
USA). The final optimized expansion medium was
named hematopoietic expansion medium (HEM). All cy-
tokines were purchased from Biopharmagen Corp.,
Suzhou, China, unless otherwise specified. All the cells
were kept and diluted with fresh medium everyday as re-
quired to maintain proper cell density ranging from 2 ×
105 to 5 × 105 cells/mL in T25, T75 flasks and turning-
bottle device (Corning, USA).
Labeling of primate mPB-derived expanded cells
Green fluorescent protein (GFP) lentivirus was prepared
as previously described [37]. Primate CD34+ cells were
cultured in the HEM. After 6-day expansion, cells were
transduced with GFP lentivirus for 8 h and then expanded
for three additional days. Cells were subsequently har-
vested for further analyses and transplantation. The trans-
duction efficiency of GFP lentiviral particles was
confirmed by flow cytometry.
Flow cytometry
Flow cytometry data were collected using a FACSVerse®
system (Becton Dickinson, NJ, USA) and analyzed using
FlowJo® software. At least 10,000 events were acquired for
each sample. The samples were analyzed for expression of
cell surface markers using fluorescein isothiocyanate
(FITC)-labeled antibodies against CD38, CD15, CD66, and
CD42b; PE-labeled antibodies against CD14, CD34, CD49f,
and CD45; PE-CY5-labeled antibody against CD90; Allo-
phycocyanin (APC)-H7-labeled antibody against CD45RA;
and APC-labeled antibodies against CD34, CD19, CD71,
and CD41a. Fluorescein isothiocyanate, PE, PE-CY5, APC-
H7, or APC-conjugated isotype-matched preimmune anti-
bodies served as controls. All antibodies were purchased
from Becton Dickinson.
Cell counting and growth curve assays
Cells were counted at various time points using the
Count Star® cell counting system. The number of CD34+
cells in each group was calculated based on the number
of total nucleated cells and the percent of CD34+ cells as
determined by flow cytometric analysis.
Colony forming unit assays
MethoCult H4230 methylcellulose medium (Stem Cell
Technologies, Vancouver, Canada) was thawed overnight
at 4 °C. Unexpanded CD34+ cells and 9-day HEM-
expanded CD34+ cells were prepared at the required
final plating concentration of 1 × 104 cells per dish. Du-
plicate cultures were prepared with 1.1 mL cell suspen-
sion in each 35-mm dish. The cells were incubated at
37 °C in 5% CO2 with > 95% humidity for approximately
16 days. Various colony-forming units (CFUs), including
erythroid burst-forming unit (BFU-E), granulocyte-
monocyte colony-forming unit (CFU-GM), megakaryo-
cyte colony-forming unit (CFU-M), and granulocyte-
erythrocyte-macrophage-megakaryocyte colony-forming
unit (CFU-GEMM) were counted with a bright-field
microscope. A colony with > 100 cells was counted as a
positive colony.
Transplantation of expanded human HSCs in NOD/SCID
mice
In vivo NOD/SCID transplantation studies were con-
ducted using human UCB CD34+ cells. A total of 64
mice were transplanted in this study. Sixteen mice were
randomly assigned to each of the following treatment
groups: normal saline; no expansion (transplanted with
1 × 105 unexpanded CD34+ cells per mouse); expansion
with HEM (low dose, transplanted with 1 × 105 ex-
panded CD34+ cells per mouse); and expansion with
HEM (high dose, transplanted with CD34+ cells ex-
panded for 9 days from 1 × 105 starting CD34+ cells).
Cells were intravenously infused into NOD/SCID mice
that were pretreated with 2.5 Gy 60Co, a sub-lethal dose
of radiation. Mouse PB samples were collected from the
retro-orbital plexus at different time points after trans-
plantation and were stained with various antibodies as
indicated in the Flow cytometry section.
Long-term engraftment was further determined by
secondary transplantation in NOD/SCID mice (n = 8).
BM cells harvested from both femurs/tibias were resus-
pended in saline and then injected into sublethally
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irradiated (2.5 Gy, 60Co) secondary NOD/SCID recipi-
ents at a ratio of one donor to one recipient.
Limiting dilution assays
The frequency of SCID-repopulating cell (SRC) in the
unexpanded or HEM-expanded cell population was de-
termined by injecting cohorts of mice (n = 40) with sev-
eral dilutions of cells (CD34+ cell number at 5000,
10000, 20,000, 30,000). Human CD45+ cell proportions
in mouse BM were determined by flow cytometry in
week 8 post cell injection. Mice with human CD45+ cell
ratio lower than 0.5% were defined as a negative. The
SRC frequency was calculated from the proportions of
negative mice in each cohort, using the L-CALC™ soft-
ware (STEMCELL™ Technologies, Vancouver, BC,
Canada), which employed Poisson statistics and the
method of maximum likelihood. After log transform-
ation, the ratio of frequencies was computed as reported
earlier [38–40].
CD34+ cell autologous transplantation in cynomolgus
primates
Cynomolgus primates were used to examine the ability
to reconstruct hematopoietic lineage of HEM-expanded
primate CD34+ cells. Transplantation was performed at
least 1 month after BM mobilization and collection. The
primates (n = 11) were given cyclophosphamide (CTX;
Energy Chemical, Shanghai, China) by intravenous injec-
tion (i.v.) at a dose of 50 mg/kg/day for successively 2
days. Nonhuman primates were randomly divided into
Table 1 Culture formula optimization for human CD34+ cell expansion
Group IMDM Nutrition Supplements SCF (ng/mL) Flt-3 L (ng/mL) TPO (ng/mL) IL-3 (ng/mL) G-CSF (ng/mL) GM-CSF (ng/mL) SR1 (μM)
GF0 + – – – – – – – –
SGF0 + + – – – – – – –
SGF2 + + 200 200 0 – – – –
SGF3 + + 200 200 5 – – – –
+ + 10 – – – –
+ + 20 – – – –
+ + 50 – – – –
+ + 100 – – – –
SGF4 + + 200 200 20 5 – – –
+ + 10 – – –
+ + 15 – – –
+ + 25 – – –
+ + 50 – – –
+ + 100 – – –
SGF5 + + 200 200 20 15 5 – –
+ + 10 – –
+ + 15 – –
+ + 25 – –
+ + 50 – –
+ + 100 – –
SGF6 + + 200 200 20 15 10 5 –
+ + 10 –
+ + 15 –
+ + 25 –
+ + 50 –
+ + 100 –
SGF7 + + 200 200 20 15 10 10 0.5
+ + 1
+ + 2
HEM + + 200 200 20 15 10 10 –
The composition of the base (GF0 and SGF0), intermediate (SGF2-SGF7), and the final optimized media formula (HEM) are shown
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following three groups: control group (n = 3) treated
with normal saline, negative control group (n = 3) trans-
planted with autologous CD34− cells, and the experi-
mental group (n = 5) transplanted with GFP-labeled,
HEM-expanded CD34+ cells along with CD34− cells.
Transplantation was conducted on day 3 after the last
CTX injection when the animals exhibited apparent
myelo-suppression.
After transplantation, routine blood tests were per-
formed using the Sysmex XT-2000iv system (Sysmex
corporation, KoBE, Japan) to monitor hematopoietic cell
recovery including white blood cells (WBC), neutrophils
(NEU), lymphocytes (LYM), and platelets (PLT). PB cells
were stained for CD45, CD14, and CD20, and then ana-
lyzed by flow cytometry to determine the contribution
of GFP+ cells to different subsets. One month after
transplantation, GFP+ cells in the CD45+ cell population
derived from primate BM was also determined.
Statistical analysis
One-way analysis of variance (ANOVA) followed by
Dunnett’s multiple comparison test was used for com-
parisons among the various treatment groups. Student’s
t test was used for comparisons between two groups. Re-
sults were considered statistically significant when the p
value was less than 0.05.
Results
Growth factor optimization for human HSC expansion
Various growth factors reagents, including TPO, IL-3,
G-CSF, GM-CSF, and SR1, were added one by one, or in
combination, into the media IMDM supplemented with
nutrition supplements, as well as SCF and Flt-3 L, to
identify the optimal concentrations needed for expand-
ing human HSCs ex vivo (Table 1). The expansion fold
of CD34+ cell was found to be maximal with TPO at 20
ng/mL, IL-3 at 15 ng/mL, G-CSF at 10 ng/mL, and GM-
CSF at 10 ng/mL. When higher concentrations of these
growth factors were used, CD34+ cell number was re-
duced, because the CD34+ ratio was decreased (Fig. 1a–
d). Our findings regarding the doses of TPO and G-CSF
were consistent with the literature [36, 37]. On the other
hand, SR1 did not elicit significant enhancement of
CD34+ cell expansion when added to media supple-
mented with the six cytokines and nutrition supplements
(Fig. 1e). Therefore, SR1 was excluded from subsequent
experiments. At the optimized concentrations of each
growth factor, the combination of the six cytokines
showed the best capability in HSC expansion (Fig. 1f ).
The final optimized HEM for human HSC expansion
was IMDM supplemented with six cytokines (SCF, TPO,
Flt-3 L, IL-3, G-CSF, and GM-CSF) and nutrition supple-
ments as indicated in Table 1.
HEM promotes expansion of HSCs isolated from various
sources
We compared the ability of HEM to expand HSCs derived
from fresh human UCB, cryopreserved human UCB, or hu-
man mPB. In general, during the first 4 days, the cells ex-
panded at a slow pace, whereas from day 4 to day 9, cells
cultured with HEM exhibited overall exponential growth
(Fig. 2a), with rapid increases in both total and CD34+ cells
(Fig. 2b). On day 4, the fold-changes in proliferation for
CD34+ cells from fresh UCB, cryopreserved UCB, and cryo-
preserved mPB were 15.63 ± 1.76, 14.41 ± 2.72, and 3.85 ±
1.02, respectively. On day 9, the fold-changes were 142.9 ±
28.4, 129.7 ± 24.3, and 50.9 ± 13.2, respectively. These re-
sults demonstrated that HEM could promote the expansion
of CD34+ cells from all three sources. There was no signifi-
cant difference between the fresh and cryopreserved human
UCB cultures with respect to rates of CD34+ proliferation,
but CD34+ cells from UCB exhibited higher proliferation
potential than those from mPB. Hence, subsequent experi-
ments were performed with cryopreserved UCB samples.
Immunophenotyping of expanded HSC
To further define whether the ex vivo expanded CD34+ cells
possessed the other acknowledged HSC’s immunologic
characteristics, including the presence of CD90 and absence
of CD45RA [41], the percentage of CD34+ cells in the
total cell population (P1) and the percentage of
CD38−CD90+CD45RA−CD49f+ cells in the CD34+ cell group
was measured (Fig. 2d–f). The proportion and absolute
number of CD34+CD38−CD90+ CD45RA−CD49f+ cells were
calculated and compared among each group (SGF 0–6) on
day-0, day-4 and day-9 (Additional file 1: Table S1). It
could be seen that the absolute number of
CD34+CD38−CD90+CD45RA−CD49f+ cells in group SGF 6
significantly increased, compared to groups SGF 2–5 on both
day 4 and day 9, indicating that HEM can support the expan-
sion of CD34+CD38−CD90+CD45RA−CD49f+ cells. The
above results indicated that although a part of initial CD34+
cells differentiated during the culture resulting in decreased
CD34+ proportion, there still existed plenty CD34+ cells
maintained self-renewal and proliferation, contributing to sig-
nificant increase of CD34+CD38−CD90+CD45RA−CD49f+
cells. In addition, we isolated HEM-expanded CD34+ cells
and performed CFU assay, and the results showed that
HEM-expanded CD34+ cells were capable of forming various
colonies including BFU-E, CFU-GM, CFU-GEMM, and
CFU-M, further proving their ability to form different types
of blood cells (Fig. 2c). The immunophenotyping of various
blood cells in HEM-expanded cells were also detected on day
0, day 4, and day-9 (Additional file 1: Table S2).
Engraftment of HEM-expanded HSCs in NOD/SCID mice
Given the lower immunogenicity and higher prolifera-
tion potential of UCB cells relative to blood cells from
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other sources, the ever-increasing feasibility of identify-
ing HLA-matched UCB HSCs from many storage facil-
ities worldwide, and the availability of UCB samples for
the current study, we conducted the in vivo NOD/SCID
transplantation studies using HEM-expanded human
UCB CD34+ cells. Engraftment of human hematopoietic
cells was determined using NOD/SCID mice subjected
to sub-lethal irradiation (radioactive source 60Co; dose
2.5 Gy; radioactive intensity 0.38 Gy/min). Flow cytomet-
ric analysis of PB and BM cells revealed that human cell
surface antigens were not expressed in cells from control
mice, which were injected with saline. Three weeks after
Fig. 1 Effect of different medium conditions on HSC expansion ex vivo. a CD34+ cell expansion with TPO concentrations ranging from 0 to 100
ng/mL in SGF2 medium (IMDM supplemented with 200 ng/mL SCF, 200 ng/mL Flt-3 L, and nutrition supplements). b CD34+ cell expansion with
IL-3 concentrations ranging from 0 to 100 ng/mL in SGF3 medium (SGF2 with 20 ng/mL TPO). c CD34+ cell expansion with G-CSF concentrations
ranging from 0 to 100 ng/mL in SGF4 medium (SGF3 with 15 ng/mL IL-3). d CD34+ cell expansion with GM-CSF concentrations ranging from 0 to
100 ng/mL in SGF5 medium (SGF4 with 10 ng/mL G-CSF). e CD34+ cell expansion with SR1 concentrations ranging from 0 to 2 μM in SGF6 medium
(SGF5 with 10 ng/mL GM-CSF). f A summary of CD34+ cell expansion in media with different growth factor combinations. SGF7 is SGF6 supplemented
with 1 μM SR1. Expansion was calculated as fold increase (after/before expansion) in cell counts on each day (days 0, 4, and 9). Data are shown as
mean ± SD, n = 6. **p < 0.01, ***p < 0.001; one-way ANOVA followed by Dunnett’s multiple comparison test
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transplantation, human CD34+ cells were detected at
2.84 ± 1.03% in mouse PB in the high-dose group
(transplanted with all the cells expanded from 1 × 105
starting CD34+ cells), whereas the proportion was
below 0.5% in both the unexpanded group (trans-
planted with 1 × 105 unexpanded CD34+ cells), and
the low-dose cell group (transplanted with 1 × 105 ex
vivo expanded CD34+ cells) (Fig. 3a). Cells from
mouse PB were also positively stained for human
CD45, CD66, CD15, CD19, CD71, CD41a, and CD42b
in all groups that received HSCs, indicating the con-
tribution of injected human HSCs to different types
of blood cells. Relative abundance of CD34+, CD45+,
CD15+, and CD19+ cells were significantly greater in
Fig. 2 Effects of HEM on the ex vivo expansion of human HSCs from different sources. Human CD34+ cells purified from fresh UCB,
cryopreserved CB, and mPB were cultured with HEM to day 4 or day 9. Total cell (a) and CD34+ cell (b) expansion was calculated as fold increase
(after/before expansion) in cell counts on each day (days 0, 4, and 9). Data are shown as mean ± SD, n = 10. c Types of CFU colonies formed from
the hematopoietic stem/progenitor cells before/after expansion. Equal numbers of unexpanded human CD34+ cells and 9-day HEM-expanded
CD34+ cells (1 × 104 per dish) were assayed as described in Methods. Data are shown as mean ± SD, n = 4. Pairwise comparisons (unexpanded vs
expanded) were performed for each type of colony using Student’s t test (p > 0.05 for all pairs). d–f Representative flow analysis for multi-
immunophenotyping of the expanded cells on day 0, day 4, and day9. Gates of CD34+ CD38−, CD90+, CD45RA−, and CD49f+ cell populations
were set based on the fluorescence minus one (FMO) of each cell surface marker antibody. CD38−, CD90+, CD45RA−, and CD49f+ were analyzed
in CD34+ cell population
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Fig. 3 Functional assessment of human cells in PB and BM of NOD/SCID mice transplanted with various types of human HSCs. Three weeks (a) and eight
weeks (b) after intravenous human CD34+ transplantation in mice, the presence of human cells was analyzed in the PB of mice transplanted with unexpanded
human HSCs, low-dose expanded HSCs, or high-dose expanded HSCs. Normal saline (NS) was injected as the vehicle control. Data are shown as mean± SD,
n = 16. c At week 8 post-transplantation, engrafted human cells were detected in the BM by flow cytometry. The percentages of cells expressing human
hematologic-lineage markers shown are calculated on the total (mouse plus human) cell population from mouse PB or BM. Data are shown as mean± SD, *
p <0.05, **p <0.01, ***p < 0.001, ****p <0.0001; one-way ANOVA followed by Dunnett’s multiple comparison test
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the high-dose expanded group than in the other
groups.
Eight weeks post-transplantation, human CD45+,
CD66+, CD15+, CD19+, CD71+, CD41a+, and CD42b+
cells were easily detectable in mouse PB in all groups
that received HSCs. The relative cell abundance in the
unexpanded group and the low-dose expanded group
was similar, whereas that of the high-dose expanded
group was significantly greater than the other groups,
for all subtypes, with the fraction of CD45+ cells reach-
ing > 20% (Fig. 3b). Moreover, compared to week 3
(Fig. 3a), abundance of most subtypes of human
hematopoietic cells in the high-dose expanded group
was significantly greater at week 8 (Fig. 3b; p < 0.001 for
CD34+, CD15+, CD45+; p < 0.01 for CD19+, CD41+,
CD66+; p > 0.05 for CD42+, CD71+).
Further analysis of mouse BM cells at 8 weeks post-
transplantation showed that CD34+ cells were at 1.43 ±
0.78% in the unexpanded group, 1.92 ± 0.93% in the low-
dose cell group, and 5.05 ± 2.71% in the high-dose cell
group (Fig. 3c). CD45 marker was positive in these three
groups at 6.50 ± 2.13%, 6.98 ± 2.72%, and 19.9 ± 8.2%, re-
spectively. Other subtypes of human hematopoietic cells
were also detected with the high-dose group showing a
significantly greater abundance than the other groups
for CD15+ and CD19+ cells.
Significantly, over 20% leukocytes isolated from mouse
BM remained positive for human CD45 at week 24 after
transplantation (Fig. 4a). Furthermore, the percentages
of the specific types of human cells in the unexpanded
group, low-dose expanded group, and high-dose ex-
panded group were 12.0% ± 2.5%, 17.4% ± 2.7%, and
22.8% ± 5.2% (***p < 0.001 among three groups) for
CD45+CD15+ myeloid cells (Fig. 4b, d), respectively, and
7.4% ± 1.9%, 5.1% ± 1.6%, and 6.2% ± 1.7% (p = 0.0684
among three groups, one-way ANOVA, no significant
difference) for CD45+CD19+ lymphoid cells (Fig. 4c, d),
respectively. These result indicated that, although there
was a trend of increase in myeloid potential, the expan-
sion procedure did not noticeably compromise the
lymphoid potential for the engraftment.
To further validate the presence of long-term repopu-
lating cells after ex vivo culture, secondary transplant-
ation was conducted. At 8 weeks after secondary
transplantation, flow cytometric analysis revealed that
cells positive for human CD45+ were at 4.25 ± 1.60%,
4.13 ± 1.71%, and 8.99 ± 3.10% among total BM cells in
the unexpanded group, the low-dose group, and high-
dose group, respectively (Fig. 4e). In addition, these three
groups of mice were all positive for human CD15+ (mye-
loid) and CD19+ (lymphoid) cells and that, while the
abundance of the myeloid lineage appeared greater in
the high-dose expanded group than in the other groups,
the lymphoid potential for the engraftment was not
compromised by the expansion procedure (Fig. 4f, g).
Therefore, it can be concluded that human HSCs de-
rived from ex vivo expansion with HEM contained a
considerable number of long-term HSCs with the ability
to repopulate in BM and differentiate into different types
of blood cells.
Moreover, limiting dilution analysis was employed to
clarify the frequency of SRCs in unexpanded CD34+ cells
and HEM-expanded CD34+ cells. As shown in Fig. 4h,
the SRC frequencies were estimated to be 1/31250 and
1/11494 in unexpanded CD34+ cells and HEM-
expanded CD34+ cells, respectively. According to the re-
sult, SRC frequency was found to be enhanced by 2.7
fold in mice that received HEM-expanded cells as com-
pared to those receiving unexpanded cells in week 8
post-transplantation. This data was consistent with the
results of immunophenotyping of the HEM-expanded
cells, which implied that long-term HSCs were enriched
in the expanded HSC group and that the HEM platform
could be used to effectively expand human HSCs.
Expansion and transduction of mobilized primate PB-
CD34+ cells
To further and better evaluate the safety and efficacy of
our expansion strategy HEM, an in vivo study in the pri-
mate model was performed as part of the preclinical
evaluation (Fig. 5a). Given that no immunosuppressed
primate models are available to test the function of ex
vivo expanded human CD34+ cells, and the difficulty in
obtaining primate UCB, we use autologous primate mPB
CD34+ cells for transplantation. CD34+ cells from non-
human primates were purified from mPB and then cul-
tured ex vivo in HEM. After a 6-day expansion period,
the cells were transduced with a GFP lentivirus and re-
expanded for three additional days. Over the 9-day cul-
ture, total nucleated cells and CD34+ cells expanded sig-
nificantly with an average of 63.7% (ranging from 55.9 to
71.7%) of CD34+ cells. Compared with the unexpanded
CD34+ cells, expanded PB CD34+ cells from the pri-
mates exhibited no significant loss in typical CD34 ex-
pression during ex vivo culture. The fold-change in
CD34+ cell expansion ranged from 6.3 to 9.8 as indi-
cated in Table 2. HEM-expanded primate CD34+ cells
retained their hematologic-lineage differentiation ability
based on the data from CFU assays (Fig. 5b).
Hematological recovery of primates after autologous
transplantation
A nonhuman primate myelo-suppression model was
established for autologous transplantation by CTX treat-
ment, resulting in remarkably declined whole blood cell
counts. CD34+ cells (ranging from 2.0 × 106 to 2.4 ×
106/kg), and CD34− cells (ranging from 2.0 × 107 to
2.6 × 107/kg) were used for autologous transplantation in
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Fig. 4 (See legend on next page.)
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primates (Table 2). Time-dependent recovery of WBC
(Additional file 1: Figure S1), PLT (Additional file 1: Fig-
ure S2), NEU (Additional file 1: Figure S3), and LYM
(Additional file 1: Figure S4) was recorded in the group
transplanted with CD34+ cells. In the autologous CD34+
transplantation group, the WBC, NEU count nadir after
transplantation declined to approximately 25% or < 25%
of the initial value whereas in the control groups, the
count nadir was 10% or < 10% of the initial value. A
range of 50 to 60% of the initial PLT count nadir was ob-
served in autologous CD34+ transplantation, whereas it
was 25~35% in both control groups. In the autologous
CD34+ transplantation group as well as in the control
groups, the LYM count nadir after transplantation was
about 10% or < 10% of the initial value. These results
showed that transplantation with expanded CD34+ cells
could improve the NEU and PLT count nadir, which is
helpful for hematological recovery.
As shown in Fig. 5f, WBC, NEU, and PLT in primate
PB were restored to their normal levels on days 10, 10,
and 9 after autologous transplantation with expanded
CD34+ cells, respectively. Restoration of WBC, NEU,
and PLT to the normal level occurred on days 19.5,
19.5, and 13, respectively, in the CD34− control group
and on days 21.5, 21.5, and 13.5 days, respectively, in
the saline control group. However, lymphocytes were
completely restored on day 20 post autologous CD34+
cell transplantation, compared to in the CD34− group
(day 21.5) or the saline group (day 25). These data
demonstrated that the expanded cells were able to
achieve superior recovery of NEU and PLT in a timely
manner following the myelo-suppressed condition.
During the first month post autologous transplantation,
the ratio of GFP+ cells in the CD45+ population was
around 1~3% in primate PB (Fig. 5c). GFP+ cells have a
higher percentage in the CD14+ subset than that in the
CD20+ subset (Fig. 5d), suggesting that the expanded
CD34+ cells had excellent properties for accelerating
hematopoietic recovery in primates, especially for the
myeloid lineage. One month after transplantation,
GFP+CD45+ cells ranging from 1.8 to 4.1% were also
detectable in primate BM (Fig. 5e), indicating that the
expanded CD34+ cells were capable of engraftment into
primate BM.
Long-term survival of primates transplanted with
expanded autologous CD34+ cells/progenitors
Two myelo-suppressed primates (one from the negative
control group and the other from the autologous CD34−
cell group) survived only 5 days after transplantation.
Both animals died of pancytopenia and acute renal fail-
ure. BM biopsy was performed at the time of euthanasia,
which confirmed a dramatic decrease in nucleated BM
cells. These observations indicated that these primates
could not withstand the CTX-induced myelo-
suppression. Contrarily, five cynomolgus primates that
received the expanded CD34+ cells were all apparently
normal during and after the course of experiment. By
18months post-transplantation, these primates contin-
ued to survive with no apparent abnormalities with re-
gard to parameters including complete blood counts,
blood chemistries, appetite, weight gain, behavior, and
social interaction. These results implied that transplant-
ation of expanded cells resulted in no adverse reactions
in primates.
Discussion
In this study, a medium formulation (HEM) of the cyto-
kine cocktail in IMDM combined with nutritional sup-
plements (selenium, putrescine, transferrin, insulin, B-27
supplements, and human serum albumin) has been suc-
cessfully developed for efficient expansion of HSCs ex
vivo, while retaining their hematologic-lineage differenti-
ation, long-term repopulation, and hematopoietic recov-
ery ability. Notably, this protocol does not require the
use of stromal cells, animal components, or gene ma-
nipulation, valuable for industrialization and clinical ap-
plications, both in efficiency and in cost.
Using HEM, we have achieved excellent expansion
of cryopreserved human UCB CD34+ cells with up to
129-fold increase and 2.7-fold increase in SRC fre-
quency after 9 days of culture. Furthermore, since
only CD34 marker alone cannot represent actual
HSCs, we measure CD38−CD90+CD45RA−CD49f+
population which has been proved to represent HSCs
that are capable of long-term engraftment after trans-
plantation [41]. The results show that the proportion
of CD38−CD90+CD45RA−CD49f+ cells in the CD34+
cell population is maintained and the absolute
(See figure on previous page.)
Fig. 4 Long-term engraftment of human cells in NOD/SCID mice. a Extent of human cell engraftment in the BM of NOD/SCID mice transplanted
with normal saline (NS; blue dots), unexpanded HSCs (red dots), low-dose expanded HSCs (green dots), and high-dose expanded HSCs (purple
dots) at 24 weeks post-transplantation. b, c Proportion of CD45+CD15+ and CD45+CD19+ cells in the three HSC transplantation groups at week 24
post-transplantation. d Representative flow cytometry of human CD45+CD15+ (myeloid) lineage and CD45+CD19+ (lymphoid) lineage in mouse
BM at 24weeks post-transplantation. e Extent of human cell engraftment in mouse BM at 8 weeks following secondary transplantation in NOD/SCID
mice. Data points are color-coded for each group as a. f, g Proportion of CD45+CD15+ and CD45+CD19+ cells in the three HSC transplantation groups
at week 8 after secondary transplantation. Data are shown as mean ± SD, n = 8 in each group. * p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; one-
way ANOVA followed by Dunnett’s multiple comparison test. h Comparison of the frequency of SRC in unexpanded CD34+ cells and HEM-expanded
CD34+ cells. The human CD45+ cell proportion in the mouse BMs was analyzed by flow cytometry 8 weeks after transplantation
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Fig. 5 Autologus transplantation in a nonhuman primate model. a Scheme for autologus transplantation in a nonhuman primate model. CTX
treatment was administered on days − 4 and − 3, and transplantation was performed on day 0. b Types of CFU colonies formed from fresh isolated
CD34+ cells (pre-expansion) and 9-day HEM-expanded cells (Post-expansion). Data are shown as mean ± SD, n = 4. c Percentage of GFP+ cells in PB
nucleated cells (CD45+ population) at various time points during the first month following autologous transplantation. d Percentage of GFP+ cells in
primate PB CD45+, CD14+, and CD20+ cell population at 1 month post-transplantation. e GFP+ cells in the primate BM CD45+ population at 1month
after transplantation. PB and BM samples were from experimental group (E-1, E-2, E-3, E-4, and E-5). BM was harvested from primate femora. f Recovery
time of white blood cell (WBC), neutrophil (NEU), platelet (PLT), and lymphocyte (LYM) were determined by comparing the baseline before/after
CD34+ cell transplantation. Blank control, n = 2; negative control, n = 2; experiment group, n = 5. The lines of each group indicate the median in
statistical analysis
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number of CD34+CD38−CD90+CD45RA−CD49f+ cells
increase up to 190-fold compared with unexpanded
CD34+ cells (Fig. 2d, e, Additional file 1: Table S1).
Cytokines and other growth factors play a vital role in
any HSC expansion system [42–45]. In previously re-
ported studies, some liquid culture systems could ex-
pand human HSCs by ~ 100-fold [6, 46–49], but at least
2 or 3 weeks ex vivo were needed. Ueda and coworkers
[50] reported that the cytokine combination consisting
of SCF, FL, TPO, IL-6, and soluble IL-6 receptor in a
medium supplemented with 20% FBS and two other
compounds achieved a 4.2-fold increase in SRC fre-
quency. However, this condition seemed not optimal,
given the addition of FBS and the low expansion folds
(total cell ~ 45.4-fold and CD34+ cell ~ 6.1-fold). Amsel-
lem and coworkers [51] provided an approach where the
HSCs were cultured on stromal cells genetically engi-
neered to secrete HOXB4, resulting in expansions of
total cells by ~ 530-fold, and CD34+ cells by ~ 122-fold,
within 4–5 weeks and increased in SRC frequency by
2.5-fold. However, it is well known that the introduction
of stromal cells may cause immunological effects in clin-
ical transplantation. Considering potentially negative
clinical effects, stromal cells, animal components, or
gene manipulation should be avoided in HSC culture
procedure. Thus, compared with above published ap-
proaches, our optimized procedure has advantages in
the relatively high CD34+ expansion fold, the mainten-
ance of long-term repopulating and hematologic-lineage
differentiation ability, and the production of clinical-
leveled pilot scale using a turning-bottle device. Besides,
it is well known that one of the most important deciding
factors for any cell source and any protocol is the associ-
ated costs. The cost of HEM is estimated as only 1/20
compared with the mostly common commercialized
HSC expansion medium. Thus, the HEM formula that
we have developed for human HSC expansion is efficient
and cost effective.
Human long-term HSCs are usually determined by
evaluating the ability of long-term repopulation in xeno-
graft models—specifically, the total engraftment time of
primary and secondary transplants should be more than
8 weeks [52]. Therefore, we have performed primary
transplantation for up to 24 weeks and secondary trans-
plantation for 8 weeks in NOD/SCID mice. The results
show that mice transplanted with unexpanded HSCs and
a low dose of expanded HSCs have similar proportions
of engraftment, and mice infused with a high dose of ex-
panded HSCs contain even more human cells, indicating
that HEM-expanded human HSCs retain BM engraft-
ment and long-term repopulation ability in vivo. Fur-
thermore, the result of limit dilution assays confirms the
frequency of long-term HSCs in HEM-expanded CD34+
cells persuasively (Fig. 4a–d).
Notably, we observed that upon 24-week engraftment
in NOD/SCID mice, the percentage of CD45+CD15+
(myeloid) population was higher in the expanded groups
than in the unexpanded group, whereas that of the
Table 2 Summary of relevant information of the cynomolgus primates before/after transplantation
Items B-1 B-2 B-3 N-1 N-2 N-3 E-1 E-2 E-3 E-4 E-5 Mediana
Age (year) 7 7 7 6 7 7 6 7 7 7 6 7
Sex Male Male Male Male Male Male Male Male Male Male Male NA
Weight (kg) 6.5 5.6 8.0 6.2 6.4 6.1 5.8 4.6 6.6 6.6 6.6 6.4
Before expansion Cell number – – – – – – 3.0×
106
2.6×
106
3.6×
106
2.7×
106
2.4×
106
2.7× 106
CD34+ cell purity
(%)
– – – – – – 76.0% 64.9% 61.5% 73.6% 72.1% 72.1%
After expansion Total cell number – – – – – – 2.0 ×
107
1.7 ×
107
2.3 ×
107
2.3 ×
107
2.2 ×
107
2.2 ×
107
CD34+ cell purity
(%)
– – – – – – 71.7% 55.9% 57.1% 68.3% 65.6% 65.6%
Expansion fold Total cell – – – – – – 8.0 7.4 6.8 10.0 10.8 8.0
CD34+ cell – – – – – – 7.5 6.4 6.3 9.3 9.8 7.5
Transduction efficiency (GFP %) – – – – – – 31.4% 37.1% 32.8% 31.2% 40.4% 32.5%
Transplant dose (per
kg)
CD34+ cell – – – – – – 2.4 ×
106
2.0 ×
106
2.0 ×
106
2.4 ×
106
2.2 ×
106
2.2 ×
106
CD34− cell – – – 2.6 ×
107
2.0 ×
107
2.5 ×
107
2.6 ×
107
2.5 ×
107
2.0 ×
107
2.5 ×
107
2.5 ×
107
2.5 ×
107
Outcome Alive Alive Died Alive Alive Died Alive Alive Alive Alive Alive NA
B-1, B-2, and B-3 were three animals in blank control; N-1, N-2, and N-3 were three animals in negative control; E-1~E-5 were five animals in experiment group
aThe median was calculated of the experiment group
Abbreviations: NA not applicable, GFP green fluorescent protein
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CD45+CD19+ (lymphoid) population was similar among
all three groups. This result indicates that, although the
HEM-expanded HSCs have a tendency to preferentially
reconstitute the myeloid lineage, their potential to re-
constitute the lymphoid lineage is as robust as unex-
panded cells. This notion is confirmed by results from
the secondary transplantation experiment, where the
abundance of the lymphoid population is also similar
among all three groups.
Although we have verified the homing and long-term
engraftment ability of HEM-expanded HSCs in the
NOD/SCID mouse model, it is still necessary to evaluate
their ability to promote hematological recovery. Because
of xenotransplantation, it is difficult to assess the mouse
hematopoietic recovery by transplanting human HSCs.
Therefore, we performed autologous transplantation of
primate HEM-expanded CD34+ cells in a myelo-
suppressed primate model. The myelo-suppressed pri-
mate model has been developed by CTX treatment,
leading to a sharp decline in multiple blood cell lineages.
Compared to the myelo-suppressed primate models gen-
erated by whole body radiation, CTX-treated primates
are more convenient for preclinical studies to evaluate
the function of expanded cells. To our knowledge, this is
the first study of transplantation of CD34+ cells in a
CTX-induced myelo-suppressed nonhuman primate
model. It is valuable for providing a new platform to
evaluate the functions of hematopoietic cells induced by
cytokines, small chemical compounds, and/or any other
ex vivo stimulating systems prior to clinical application.
Using the same culture medium, the expansion effi-
ciency of CD34+ cells derived from primate mPB was
relatively lower than that obtained from humans. The
possible explanation for this observation may be that the
cytokines used are all recombinant human proteins,
which results in reduced activities on primate cells. In
addition, culture conditions for primate cells are not op-
timized because our goal is only to validate the safety
and efficacy of HEM-expanded CD34+ cells in primates.
Nevertheless, our findings demonstrate that nonhuman
primate CD34+ cells could also be expanded to the level
of clinical significance.
The results of primate autologous transplantation have
proved that HEM-expanded CD34+ cells can shorten the
period of pancytopenia and enhance the hematological re-
covery after myelo-suppression. Primates transplanted
with the expanded CD34+ cells exhibited superior
hematopoietic recovery compared to control groups and
showed no adverse effects as long as 18months after
transplantation, whereas both control groups (CD34- or
saline) showed death on day 5 post-transplantation. More-
over, the expanded CD34+ cells could increase the count
nadir of NEU and PLT and reduce the susceptibility to in-
fection following transplantation, thus enhancing survival.
In addition, NEU, WBC, and PLT from primates trans-
planted with the expanded CD34+ cells were restored to
normal levels (approximately within 1.5–2 weeks) faster
than LYM (3 weeks), and the median time of LYM recov-
ery did not show a significant difference compared with
the control groups. Furthermore, at 1month post-
transplantation, the subset staining results from primate
PB demonstrated that GFP+ cells were higher in CD14+
(myeloid) population than in the CD20+ (lymphoid) popu-
lation. Coincidentally, we also observed that upon second-
ary transplantation in NOD/SCID mice, the percentage of
CD45+/CD15+ (myeloid) population was higher than that
of the CD45+/CD19+ (lymphoid) population. All these re-
sults indicate that HEM-expanded CD34+ cells preferen-
tially reconstitute the myeloid lineage.
In primates transplanted with GFP-labeled cells, the
percentage of GFP+ cells was relative low and they could
not be detectable by 3~6months post-transplantation. In
terms of the low GFP percentage and short detection
window, there may be two reasons: (1) the transduction
efficiency of GFP lentiviral particles for expanded pri-
mate cells is only between 30 and 40% (Table 2), which
may cause the detected GFP+ cells to be less than totally
engrafted CD34+ cells; (2) there are still some residual
primate bone marrow cells after myelo-suppression by
CTX, and these cells could be recovered over time. As a
result, exogenously labeled GFP+ cells could be diluted
as the residual primate HSCs gradually recover.
Successful transplantation with autologous CD34+
cells in the nonhuman primate model strongly suggests
a possible application for treating certain blood diseases.
The effectiveness of the HEM expansion strategy applies
not only to UCB cells, but also to HSCs derived from
mPB, where approximately 50 CD34+ cells could be
obtained via ex vivo expansion from a single human
mPB-derived CD34+ cell. We propose that personalized,
autologous transplantation can be developed for certain
blood-related diseases, such as leukemia, using normal
CD34+ cells isolated from a small volume of mPB after
efficient ex vivo expansion in HEM. This strategy would
minimize the suffering of patients due to the use of
blood cells isolated through conventional approaches.
Furthermore, given that there are many state-of-the-art
facilities that store human UCB HSCs worldwide, it is
also convenient to search for HLA-matched UCB HSCs.
The amount of expanded HSCs derived from one CB
unit (including those with lower CD34 content) was, in
theory, still sufficient for adult (with an average weight
of 70 kg) transplantation to treat malignant blood
disorders.
Conclusions
In conclusion, we have developed a new, low-cost
medium formulation (HEM) that can greatly enhance
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the expansion of HSCs while retaining their long-term
repopulation, hematologic-lineage differentiation and
hematopoietic recovery ability. Moreover, autologous
transplantation studies in nonhuman primates strongly
suggest that HEM-expanded CD34+ cells could be safe
and efficacious in potential clinical applications.
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